Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$138.0K-88.96%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shawn K. Singh
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Beta
- 0.39
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -37.00
Financials
Revenue
$138.0K-89.0%Net Income
$-10.74MEBITDA
$-10.74MFree Cash Flow
$-12.16MEPS (diluted)
$-0.24Shares Outstanding (diluted)
44.44M+15806.0%Operating Expenses
$11.07MCash & Debt
$20.03MReturn of Capital
$0.00Revenue by Segment (annual)
$1.11MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.27M | $-69.69M | $-1.83 |
| 2025 | $486.0K | $-51.42M | $-1.67 |
| 2024 | $1.06M | $-29.36M | $-1.52 |
| 2023 | $-227.0K | $-59.25M | $-8.51 |
| 2022 | $1.11M | $-47.76M | $-7.38 |
| 2021 | $1.09M | $-17.93M | $-14.74 |
| 2020 | $0.00 | $-20.77M | $-14.21 |
| 2019 | $0.00 | $-24.59M | $-25.83 |
| 2018 | $0.00 | $-14.35M | $-30.98 |
| 2017 | $1.25M | $-10.26M | $-40.85 |
| 2016 | $0.00 | $-47.22M | $-801.28 |
| 2015 | $0.00 | $-13.89M | $-318.27 |
| 2014 | $0.00 | $-2.97M | $-81.00 |
| 2013 | $200.4K | $-12.89M | $-426.99 |
Valuation
VTGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·9d ago·Neutral
Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs Collaboration combines Vistagen's neuroscience expertise and datasets with GATC Health's predictive modeling capabilities to provide additional insights for protocol development and resource allocation Collaboration combines Vistagen's neuroscience expertise and datasets with GATC Health's predictive modeling capabilities to provide additional insights for protocol development and resource al
View source ↗ - Newsschaeffersresearch.com·58d ago·Positive
2 Falling Stocks Call Traders Are Targeting Today Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and Vistagen Therapeutics (NASDAQ:VTGN) drawing bullish options activity as both equities trade lower.
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
…ull poster presentation can be found on “Publications” section of Company's website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans.
View source ↗ - Newsglobenewswire.com·61d ago·Positive
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months
View source ↗ - Newsglobenewswire.com·73d ago·Neutral
Vistagen to Present at Psych Congress 2026 Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $-0.26 per share
Typical surprise +11.9% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.24 vs $-0.38beat
- Fri, Aug 14$-0.30 vs $-0.36beat
- Mon, Jun 15$-0.37 vs $-0.42beat
- Thu, Feb 12$-0.45 vs $-0.51beat
- Thu, Nov 13$-0.54 vs $-0.51miss
- Thu, Aug 7$-0.47 vs $-0.47beat
Estimates and results for VTGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VTGN officers and directors.
- Bought
- $18.1m
- Sold
- $107k
4 trades
2 trades
- Commodore Capital Lpbought
- Gin Jerry Bbought
- Adler Reid G.bought
- Singh Shawnbought
- Shah Nimish Psold
- Venrock Healthcare Capital Partners Ii, L.p.sold
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VTGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
